2-Amino-5-(1-aminoethenylamino)pentanal

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Amino-5-(1-aminoethenylamino)pentanal
• 英文别名: 2-amino-5-(1-aminoethenylamino)pentanal
• 化学式: C₇H₁₅N₃O
• 分子量: 157.21
• InChiKey: QSOGHKSRQXQPAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  81.1
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• US20140271468A1
  申请人：——

  公开号：US20140271468A1

  公开（公告）日：2014-09-18
• DRUG DELIVERY CONJUGATES CONTAINING UNNATURAL AMINO ACIDS AND METHODS FOR USING
  申请人：ENDOCYTE, INC.

  公开号：US20150258203A1

  公开（公告）日：2015-09-17

  Described herein are drug delivery conjugates for targeted therapy. In particular, described herein are drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids that are useful for treating cancers and inflammatory diseases. The invention described herein pertains to drug delivery conjugates for targeted therapy. In particular, the invention described herein pertains to drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids.
• Compounds for Positron Emission Tomography
  申请人：ENDOCYTE, INC.

  公开号：US20160287731A1

  公开（公告）日：2016-10-06

  Described herein are compounds, compositions, and methods for diagnosing and/or monitoring pathogenic disease using positron emission tomography. Also described are conjugates of the formula B-L-P, wherein B is a radical of a targeting agent selected from vitamin receptor binding ligands (such as folate), PSMA binding ligands, or PSMA inhibitors; L is a divalent linker comprising aspartic acid, lysine, or arginine, and P is a radical of an imaging agent or radiotherapy agent, such as a radionuclide or radionuclide containing group, or a radical of a compound capable of binding a radionuclide, such as a metal chelating group.
• CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS
  申请人：ENDOCYTE, INC.

  公开号：US20160361376A1

  公开（公告）日：2016-12-15

  The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.
• US8765096B2
  申请人：——

  公开号：US8765096B2

  公开（公告）日：2014-07-01